Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

This publication has 10 references indexed in Scilit:

• Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone
  International Journal of Radiation Oncology*Biology*Physics, 1995
• Surrogate markers in aids and cancer trials
  Statistics in Medicine, 1994
• Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time
  International Journal of Radiation Oncology*Biology*Physics, 1993
• Randomized trials in loco-regionally confined prostate cancer: Past, present, and future
  Seminars in Radiation Oncology, 1993
• Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials.
  Journal of Clinical Oncology, 1991
• Total Androgen Ablation: American Experience
  Urologic Clinics of North America, 1991
• Total Androgen Ablation: European Experience
  Urologic Clinics of North America, 1991
• Prostate-Specific Antigen for Staging Prior to Surgery and for Early Detection of Recurrence After Surgery
  Urologic Clinics of North America, 1990
• Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: Preliminary results of RTOG 83-07
  International Journal of Radiation Oncology*Biology*Physics, 1989
• Extended field (periaortic) irradiation in carcinoma of the prostate—analysis of RTOG 75-06
  International Journal of Radiation Oncology*Biology*Physics, 1986